Table 4.
Data on Irinotecan-temozolamide salvage regimen in recurrent/refractory Ewing sarcoma family tumors
| Ref. | n | Irinotecan schedule | ORR (n) | Toxicity (grade 3 and 4) |
| Kurucu et al[65] | 20 | 20 mg/m2 (D1-5 and D8-D12) | 55% (11) | Diarrhea - 9.2% |
| Neutropenia - 11.3% | ||||
| McNall-Knapp et al[64] | 25 | 15 mg/m2 vs 20 mg/m2 (D1-5 and D8-D12)1 | 20% (5) | Diarrhea - 5% |
| Raciborska et al[63] | 22 | 50 mg/m2 (D1-D5)1 | 50% (12) | Diarrhea - 15% |
| Hematological - 10% | ||||
| Wagner et al[62] | 16 | 10-20 mg/m2 (D1-5 and D8-D12) - 3 weekly vs 4 weekly | 25% (4) | Diarrhea - 11% |
| Casey et al[61] | 20 | 20 mg/m2 (D1-5 and D8-D12) | 63% | Diarrhea - 4.5% |
| Hematological - 22% |
1
With vincristine. ESFT: Ewing sarcoma family of tumors; n: Number; ORR: Overall response rate.